|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Is endoscopic ultrasound examination necessary in the management of esophageal cancer?显示文摘Despite substantial efforts at early diagnosis, accurate staging and advanced treatments, esophageal cancer(EC) continues to be an ominous disease worldwide. Risk factors for esophageal carcinomas include obesity, gastroesophageal reflux disease, hard-alcohol use and tobacco smoking. Five-year survival rates have improved from 5% to 20% since the 1970 s, the result of advances in diagnostic staging and treatment. As the most sensitive test for locoregional staging of EC, endoscopic ultrasound(EUS) influences the development of an optimal oncologic treatment plan for a significant minority of patients with early cancers, which appropriately balances the risks and benefits of surgery, chemotherapy and radiation. EUS is costly, and may not be available at all centers. Thus, the yield of EUS needs to be thoughtfully considered for each patient. Localized intramucosal cancers occasionally require endoscopic resection(ER) for histologic staging or treatment; EUS evaluation may detect suspicious lymph nodes prior to exposing the patient to the risks of ER. Although positron emission tomography(PET) has been increasingly utilized in staging EC, it may be unnecessary for clinical staging of early, localized EC and carries the risk of false-positive metastasis(over staging). In EC patients with evidence of advanced disease, EUS or PET may be used to define the radiotherapy field. Multimodality staging with EUS, crosssectional imaging and histopathologic analysis of ER, remains the standard-of-care in the evaluation of early esophageal cancers. Herein, published data regarding use of EUS for intramucosal, local, regional and metastatic esophageal cancers are reviewed. An algorithm to illustrate the current use of EUS at The University of Texas MD Anderson Cancer Center is presented. | Tomas DaVee Jaffer A Ajani Jeffrey H Lee | 2017 | World Journal of Gastroenterology2017，23，5： | 11 |
| 2 | Medical management of gastric cancer:A 2014 update显示文摘Gastric cancer represents a serious health problem on a global scale. It is the second leading cause of cancer-related death worldwide. Novel therapeutic targets are desperately needed because the meager improvement in the cure rate of about 10% realized by adjunctive treatments to surgery is unacceptable as > 50% patients with localized gastric cancer succumb to their disease. Either postoperative chemoradiotherapy(United States),pre-and post-operative chemotherapy(Europe),and adjuvant chemotherapy after a D2 resection(Asia) can all be regarded as standards of care in the localized gastric cancer management. In metastatic disease the addition of trastuzumab to chemotherapy is standard of care in Her2 positive disease. In the HER2 negative population,the treatments remain limited.In the first line setting,the standard of care is a combination of fluoropyrimidine and platinum containing chemotherapy,with or without epirubicin or docetaxel.The results of targeted therapy trials have by and large been disappointing,but none of these trials looked at an appropriately enriched population.Finally there is a meager overall survival benefit in treating patients with metastatic disease in the second line setting,with either irinotecan,docetaxel or ramucirumab however none of these drugs have been compared head to head in a well-powered randomized controlled trial. | Elena Elimova Hironori Shiozaki Roopma Wadhwa Kazuki Sudo Qiongrong Chen Jeannelyn S Estrella Mariela A Blum Brian Badgwell Prajnan Das Shumei Song Jaffer A Ajani | 2014 | World Journal of Gastroenterology2014，20，38： | 10 |
| 3 | Endoscopic management of esophageal cancer显示文摘Esophageal cancer(EC)generally consists of squamous cell carcinoma(which arise from squamous epithelium)and adenocarcinoma(which arise from columnar epithelium).Due to the increased recognition of risk factors associated with EC and the development of screening programs,there has been an increase in the diagnosis of early EC.Early EC is amenable to curative therapy by endoscopy,which can be performed by either endoscopic resection or endoscopic ablation.Endoscopic resection consists of either endoscopic mucosal resection(preferred in cases of adenocarcinoma)or endoscopic submucosal dissection(preferred in cases of squamous cell carcinoma).Endoscopic ablation can be performed by either radiofrequency ablation,cryotherapy,argon plasma coagulation or photodynamic therapy,amongst others.Endoscopy can also assist in the management of complications post-esophageal surgery,such as anastomotic leaks and perforations.Finally,there is a growing role for endoscopy to manage end-of-life palliative symptoms,especially dysphagia.The growing use of esophageal stents,debulking therapy and dilation can assist in improving a patient’s quality of life.In this review,we examine the multiple roles of endoscopy in the management of patients with EC. | Osman Ahmed Jaffer A Ajani Jeffrey H Lee | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 6 |
| 4 | Clinical trials of vascular brachy-therapy for instent restenosis : update显示文摘 | Ajani A Kim HS Waksman B | 2001 | Cardiovasc Badiat Med2001，2，： | 1 |
| 5 | Everolimus for previous- ly treated advanced gastric eaneer:resuhs of the randomized, double-blind,phase Ⅲ GRANITE-1 study 显示文摘 | Ohtsu A Ajani JA Bai YX | | J Clin On- col0，31，31： | 1 |
| 6 | Risk factors for ARMD, The eye disease case control study group 显示文摘 | Seddon J M Ajani U A Sperduto R D | 1992 | Arch Opht1992，110，： | 1 |
| 7 | Docetaxel for gastric and esophageal carcinomas显示文摘 | Ajani J A | 2002 | Oncology2002，16，6： | 1 |
| 8 | A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma 显示文摘 | Blum M Suzuki A Ajani JA | 2011 | Future On- col2011，7，6： | 1 |
| 9 | Dietary caroteniods, vitamin A, C, and E, and advance dage-related macular degeneration 显示文摘 | Seddon J M Ajani U A | 1994 | J Am Med Assoc1994，，272： | 1 |
| 10 | Docetaxel for gastric and esophageal carcinomas显示文摘 | Ajani J A | | 0，，： | 1 |
| 11 | Phase II study of taxol in patients with advanced gastric carcinoma显示文摘 | Ajani J A Fairweather J Dumas P | 1998 | Cancer J Sci Am1998，4，4： | 1 |
| 12 | Docetaxel-based chemotherapy in the treatment of gastric cancer显示文摘 | ROTH A D AJANI J | 2003 | Ann Oncol2003，14，2： | 1 |
| 13 | Brief review of advances in the treatment of gastric carcinoma in North America and Europe 1995 ~ 2001显示文摘 | JIWA N M KASAKURA J AJANI A | 2002 | Int J Clin Oncol2002，7，6： | 1 |
| 14 | A comprehensive review of S - 1 in the treatment of advanced gastric adenoeareinoma显示文摘 | Blum M SuZuki A Ajani JA | 2011 | Future Oncol2011，7，6： | 1 |
| 15 | Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially respectable gastric carcinoma显示文摘 | Ajani J A Manstield P F Janjan I V | 2004 | J Clin Oncol2004，22，14： | 1 |
| 16 | Phase Ⅱ multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric,or gastroesophageal adenocarcinoma显示文摘 | Ajani J A Fodor M B Tjulandin S A | 2005 | J Clin Oncol2005，23，24： | 1 |
| 17 | Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis显示文摘 | WAKSMAN R AJANI A E WHITE R L | 2004 | Circulation2004，109，3： | 1 |
| 18 | Dietary caroteniods, vitamin A, C, and E, and advanced age -related macular degeneration 显示文摘 | Seddon J M Ajani U A | 1994 | Journal of the American Medical Association1994，，272： | 1 |
| 19 | Long-term outcome of phase Ⅱtrial evaluating chemotherapy,chemoradiotherapy,and surgery for locoregionally advanced esophageal cancer显示文摘 | Swisher S G Ajani J A Komaki R | 2003 | Int J Radiat Oncol Biol Phys2003，57，1： | 1 |
| 20 | Phase Ⅱ study of Taxel in patients with advanced gastric cacinoma显示文摘 | Ajani J A Fairweather J Dumas P | 1998 | Cancer J Sci Am1998，4，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员